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over the first 24 hours, fast response as deltaMPA≥10% within the first hour after
loading (the others being slow responders), and high post-treatment platelet reacti-
vity (HPPR) as MPA≥56.56% (fourth quartile). Inflammatory markers (PAC1 and
P-selectin) and VASP were also evaluated according to onset of action.
Results: 55% of patients were slow responders. Non current smoking and
BMI ≥ 25 kg/m_ were associated with slower and lower response. HPPR was
more frequent in slow responders (28% vs 14% p<0.0001). There was a dose
effect relationship on deltaMPA, with a trend for faster onset of platelet inhi-
bition in the 900 mg LD group. Slow responders had slower and lower
decrease of PAC1 and P-selectin, and higher VASPindex at 6 hours (76.5% vs
66.4%, p=0.019) and 24 hours (70.3% vs 61.5%, p=0.049).
Conclusions: Slow response to clopidogrel is a reliable marker of low res-
ponse at 24 hours and HPPR. Whether early detection and correction of slow
clopidogrel response is clinically relevant remains to be demonstrated. 
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Background: Despite encouraging short-term results with drug-eluting
stents (DES) in diabetes mellitus (DM) patients (pts) with coronary artery
disease, the long-term safety is not clear. We investigated the influence of
long-term (> 12 months) dual antiplatelet treatment (APLT) with aspirin and
clopidogrel on clinical outcome in DM pts treated with DES.
Methods: The study included 552 consecutive DM pts (male 81%, mean age
65+9 years) that had been treated with DES and received dual APLT treatment for
12 months. Long-term clinical follow-up (FU) (mean time 30.4 + 11.6 months),
obtained in 545/552 (99%) of them; 419 (77%) pts were on dual APLT (group A)
and 126 (23%) on single APLT (group B). Major adverse cardiovascular event
(MACE) on clinical FU was considered death (D), myocardial infarction (MI),
percutaneous or surgical revascularization (REV), cerebrovascular accident
(CVA), and hard end-points (HDP) was considered D, MI and CVA. Late stent
thrombosis (LST) was defined as angiographic documentation of stent occlusion
associated with an acute ischemic event, unexplained sudden D or MI not clearly
attributable to another coronary lesion > 12 months post-procedure.
Results: Unstable angina at presentation was more frequent in group A pts
(36% vs. 26%, p<0.05).The incidence of LST was 2.1% in group A and 0.8%
in group B pts (p:ns); no difference was observed according to diabetic treat-
ment (insulin vs. non-insulin dependent). At FU D was observed in 4.8% vs.
2.4%, MI 1.9% vs. 0.8%, and HDP in 8.4% vs. 4% between pts in group A
and B respectively (p:ns). The rate of any REV and MACE was higher in pts
in group A (20.3% vs. 6.3 %, and 26.7% vs. 11.1%, p<0.001); this difference
was only observed in non-insulin-dependent pts. In a multivariate model ejec-
tion fraction <40% was predictor for LST (HR 14.5, 95% CI 3.9-49.4,
p<0.001), and D/MI (HR 3.61, 95% CI 1.7-7.5, p=0.001), and multivessel
disease for MACE (HR 2.0,95% CI 1.27-3.15, p=0.003).
Conclusion: Dual APLT > 12 months in DM pts treated with DES implan-
tation is not associated with better clinical outcome or lower risk of LST. 
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Primary coronary angioplasty (PCA) of unprotected left main coronary
artery (LM) in patients (pts) with cardiogenic shock (CS) is a high-risk proce-
dure, carrying a high morbi-mortality. 
Accordingly we aimed to assess the prevalence, clinical presentation, the-
rapeutic workout and in-hospital and long-term prognosis of pts presenting
with CS due to TIMI flow 0-1 LM thrombosis.
Over a 6-years period, and out of a prospective cath-lab database of 6062
files, 17 cases of CS secondary to LM thrombosis were identified and con-
firmed by reanalysis of angiograms. Therapeutic management and in-hospital
outcome were obtained from medical files and prospective follow-up was
obtained.
The study population consisted in 13 men (76%) with a mean age of 64±16
years, corresponding to a prevalence of 0.28 % of pts proposed for coronary pro-
cedure. Clinical presentation was an ACS with and without persistent ST-eleva-
tion in 11 (65%) and 6 cases (35%) respectively. Five patients (29%) received
pre-hospital thromboysis, which failed to achieved reperfusion in all cases.
Twelve patients (71%) undergone mechanical support (intra-aortic balloon pum-
ping alone in 55%, extracorporeal life support alone in 5%, and both in 45%).
The majority of PCA were performed with bare metal stent (n=14, 82%), under
GPIIbIIIa antagonists in 8 cases, and instrumental thrombectomy in 3 cases. In-
hospital death occurred in 5 pts (29%). At mean follow-up of 23 months (100%
completed) survival rate was 53% for entire cohort and 75% among discharged
pts. Most patients were in NYHA class I (7/9), with averaged left ventricular
ejection fraction of 50+17%. One pts was implanted with a Thoratec device and
is awaiting heart transplantation, and one is in terminal heart failure.
LM occlusion with CS has a very high mortality rate. However, PCA in such
setting with use of aggressive mechanical life support carries an acceptable level
of major adverse coronary event at medium and long-term prognosis. 
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Background: In ACS patients, presence of a peripheral arterial disease
(PAD) or a low ankle brachial index (ABI) is associated with a higher CV risk
in either symptomatic or asymptomatic PAD patients than ACS patients
without PAD.
Objective: To determine the frequency and describe symptomatic and
asymptomatic PAD patients, diagnosed by clinical examination and ABI
measurement, in French population with recent history of ACS.
Methods: A 2-stage observational survey was conducted by 422 office-
based cardiologists: 1) a registry part to provide a nationally representative
overview and to estimate the prevalence of PAD and proportion of normal or
low ABI in the overall.
2) a detailed part to asses and compare patients issued from registry with
symptomatic or asymptomatic PAD and without PAD.
Results: 374 office based cardiologists recorded in the registry 2030
patients with a recent history of ACS and selected 1135 patients for the
detailed part of the study.
Main characteristics of the registry patients were: mean age 66 years, 75%
male, 30.3% STEMI, 22.7% NSTEMI and 47.1% UA. The prevalence of PAD
in the registry population was 35.9% and between them 401 (55.1%) were
symptomatic: intermittent claudication (321), history of angioplasty or bypass
(221), amputations (12). Mean value of ABI measurement in the registry was
0.93 CI [0.92-0.94] with 32.3% less than 0.9.
In the detailed part of the study, the mean age was 65.7 years and 77.7%
of patients were male. ACS characteristics: STEMI 32.1%, NSTEMI 22.4%
and UA 45.5%. 624 patients were selected without PAD and 511 with PAD.
Within these patients, 55.4% were symptomatic: intermittent claudication
(20.3%), had a history of angioplasty or bypass (12.6%), or amputations
(0.4%). Mean value of ABI for 1131 patients in the detailed study was 0.9
[0.89-0.91] and 42% had a low ABI (<0.9).
Conclusions: PAD is highly prevalent (35.9%) in patients with recent his-
tory of ACS and almost one half of these patients are asymptomatic.
